Dr Reddy’s Laboratories (RDY) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr. Reddy’s Laboratories reported a 17% year-over-year increase in revenue for the second quarter, reaching ₹80,162 million, driven by strong growth in global generics and emerging markets. Despite the rise in revenues, the company faced a decline in profit after tax attributable to equity holders, which fell by 15% year-over-year. The Board also approved a significant investment in its Russian subsidiary to support working capital needs, reflecting its ongoing commitment to strengthening core businesses and expanding market presence.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.